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I~  Sodium 4-phenylbutyrate induces Ik-8 expression in CF lung 
epithelial cells through an ERKl/2-dependent pathway 
E. Boncoeur, T. Roque, O. Tabary, E. Bonvin, A. Clement, A. Henrion-Caude, 
J. Jacquot. INSERM, UMR S 719, Universitd Pierre et Marie-Curie-Paris6; H@ital 
Saint-Antoine, Paris', F-75012, France 
Sodium 4-phenylbutyrate (4-PBA), a butyrate analogue that is approved for clinical 
use in cystic fibrosis (CF) lung disease, has been shown to correct he AF508-CFTR 
trafficking defect, to restore CFTR function at the plasma membrane of cultured CF 
lung epithelial cells and to cause a improvement in nasal epithelial chloride transport 
in AF508-homozygous cystic fibrosis patients. The aim of our study was to gain 
insights into the potential effects of 4-PBA on the inflammatory esponse in CF lung 
epithelial cells. With two CF bronchial epithelial cell types (CFBE140- and IB3 1 
cell lines with AF508-homozygous and heterozygous genotype, respectively), we 
clearly demonstrated that 4-PBA induced a strong increase of both IL-8 mRNA 
and protein expression in two CF cell lines whereas no significant variation of IL- 
l~J mRNA was observed. Unexpectedly, we also reported that treatment of IB3 1 
cells with 4-PBA alone (10 mM) or in combination with 10 ng/ml TNF-o. did not 
increase the NF-~;B transcriptional activity and reduced the 20S proteasome activity. 
These data prompted us to investigate other potential pathways controlling the 
IL-8 expression by 4-PBA. Inhibition of ERK1/2 signalling pathway by U-0126 
blocked the increase of 4-PBA mediated IL-8 expression, suggesting that ERK 
regulated 4-PBA mediated IL-8 expression i  an NF-~;B-independent manner. Thus, 
a combination of 4-PBA treatment with an ERK inhibitor may be beneficial to 
reduce the lung inflammation i CF patients. 
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1~ Presence of 1~3-adrenoceptor in human lung: overexpression in 
Cystic Fibrosis 
F. Bossard 1 , G. Toumaniantz 1 , A. Robay 3, I. Danner 2, C. Sagan 2, C. Gauthier 1 .
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The f3-adrenergic stimulation exerts a variety of effects on airway epithelial cells: 
increased ciliary beat frequency, opening of apical ion channels uch as Cystic 
Fibrosis Transmembrane conductance Regulator (CFTR). Three f3-adrenoceptors 
(~J-AR) subtypes could be involved. ~Jl-AR and ~J2-AR activate the cAMP pathway, 
however they are desensitized under a chronic agonist exposure. In a heterologous 
expression system, we have shown that f33-AR activates CFTR chloride activity 
independently of cAMP (Leblais et al., 1999, J Biol Chem), but through a 
Gi/PI3Kinase-MAPKinase pathway (Robay et al., 2005, Mol Pharmacol). As no 
study reports the presence of f33-AR in the human lung, the aim of this work was 
to determine its presence in human lung samples and its expression level in CF 
vs. non-CF patients. Human bronchial samples used for controls were obtained 
from non-CF patients who underwent a partial lung resection. CF tissues were 
obtained after a lung graft. ~J3-AR mRNAs and ~J3-AR proteins were assayed by 
PCR and western-blotting respectively. Immunostainings allowed to determine the 
histological localisation of ~J3-AR. CF and non-CF ~J3-AR expression levels were 
investigated by real-time PCR. By PCR and western-blotting, we detected in all 
control (n 4) and CF (n 3) samples the presence of ~J3-AR. This receptor was 
mainly immunolocalised in ciliated epithelial cells. By real-time PCR, we observed 
a 3 4 fold-overexpression of f33-AR mRNA in CF samples. This study demonstrates 
for the first time a f33-AR expression in human lung epithelia. Its overexpression 
in CF suggests a role of ~J3-AR in this pathology and opens new prospects for 
therapeutic nvestigations through f33-AR modulation. 
I •  ERKI/2 activation and Ik-8 secretion of Cystic Fibrosis lung 
epithelial cells in response to oxidative stress 
E. Boncoeur, E. Bonvin, C. Muselet-Charlier, A. Clement, J. Jacquot, O. Tabary. 
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Dysregulated IL-8 production is reported in lung epithelium of cystic fibrosis (CF) 
patients. We here document he impact of cystic fibrosis transmembrane con- 
ductance regulator (CFTR) dysfunction on the production of interleukin (IL)-8, 
expression of its CXCR1/2 receptors and the involvement of MAP kinase and NF- 
KB pathways in cystic fibrosis (IB3 1) and ($9) corrected lung epithelial cell lines 
in response to oxidative stress. We show that expression of both IL-8 and CXCR1/2 
receptors is increased in both IB3 1 and $9 cells in response to oxidative stress. 
Activation of p38 and JNK MAP kinase is similar in the two IB3 1 and $9 cells 
after oxidative stress. Surprisingly, in contrast o that observed in $9 cells, this 
is accompanied with no NF-~;B activation but a marked ERK1/2 MAP kinase 
activation is observed in IB3 1 cells. Using a series of chemical inhibitors, we 
show that the strongest reduction in both IL-8 and CXCR1/2 expression is obtained 
by treatment of $9 cells with NF-~;B inhibitor BAY 11 17082 and with ERK1/2 
inhibitor UO126 for IB3 1 cells. Our results point out a switch from NF-~;B to 
ERK1/2 signaling in IB3 1 cells for the regulation of both IL-8 production and 
CXCR1/2 expression upon oxidative stress. 
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I • A  long-acting 1~2-adrenergic receptor agonist increases hydration 
and mucus exocytosis in human tracheal glandular cells 
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The regulation of CFTR activity is under the activation of surface G protein 
coupled receptors (GPCR) such as ~J2-adrenergic receptor. Many compounds such 
as the long-acting ~J2-agonist (LABA) salmeterol have been shown to activate 
CFTR through activation of GPCR, which increases the forskolin activated-chloride 
efflux in the CF-KM4 cells (Castillon et al, 2004). We have earlier shown that 
CFTR protein expression was increased by exposure to the LABA salmeterol 
(Taouil et al, 2003). In addition, we demonstrated an increased ion content 
and decreased hydration of mucus inside the secretory granules in parallel with 
a deficient secretory granule expansion through a CFTR-dependent mechanism 
(Baconnais, Delavoie et al, 2005). In this study, we further explored the effect 
of the LABA salmeterol on the hydration by quantitative dark field intensity, the 
ion composition by X-ray microanalysis and the expansion of the secretory granules 
by phase-contrast videomicroscopy in a CF human tracheal glandular cell line (CF- 
KM4). X-ray microanalysis showed that compared to control, the LABA salmeterol 
induces in secretory granules a significant (P < 0.01) decrease of Na, C1, P and S 
concentration a d a significant increase (P < 0.001) of the hydration. In parallel, we 
observed that the LABA salmeterol induces enhancement of mucus exocytosis. The 
incubation of the salmeterol-treated CF cells with a CFTR inhibitor (CFTRinh-172) 
induced a lower mucus exocytosis. These results suggest hat through a CFTR- 
dependent mechanism, the LABA salmeterol is able to improve the hydration of 
mucus and therefore may facilitate the process of mucus exocytosis in CE 
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